



Practitioner's Docket No. MPI00-212CP1CN1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The application of: Coyle, Anthony J., et al

Application No.:

Group No.:

Filed: Herewith

Examiner:

For: B7-H2 POLYPEPTIDES

Mail Stop Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements
2. Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449) (3 pages)
3. Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Addressee"

Mailing Label No. EL992152772US

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.


Signature
Sean Hunziker
(type or print name of person certifying)

Date: August 20, 2003

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

COPY

Preliminary Statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Identification of Prior Application in Which Listed Information Was Already Cited
and for Which No Copies Are Submitted or Need Be Submitted**

This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior application Serial Nos. 09/910,174 filed on July 20, 2001, and 09/620,461 filed on July 20, 2000.

The cited references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application. However, the undersigned will provide additional copies upon request.

Respectfully submitted,

August 20, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By Kerri Pollard Schray
Kerri Pollard Schray
Registration No. 47,066
75 Sidney Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820

Substitute for form 1449A/PTO

DEC 18 2006

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	
Filing Date	Herewith
First Named Inventor	Coyle, Anthony J., et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	MPI00-212CP1CN1M

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
A1	5,521,288			Linsley et al.	05/28/1996	
A2	5,861,310			Freeman et al.	01/19/1999	
A3	5,942,607			Freeman et al.	08/24/1999	
A4	5,968,510			Linsley et al.	10/19/1999	
A5	US-2002/0095024	A1		Mikesell et al.	7-2002	
A6	US-2002/0164600	A1		Freeman et al.	11-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Kind Code ⁵ Number ⁴ (if known)				
B1	WO	96/40915		Dana-Farber Cancer Institute	12/19/1996	All	
B2	EP	1074617	A	Helix Res Inst	February 7, 2001		
B3	WO	01/83750	A	Tseng et al.	November 8, 2001		
B4	WO	01/94413	A	Squibb Bristol Myers	December 13, 2001		
B5	WO	01/34629	A	Human Genome Sciences Inc	May 17, 2001		
B6	WO	00/55375	A	Alphagene Inc	September 21, 2000		
B7	WO	00/37643	A	Corixa Corp	June 29, 2000		
B8	WO	01/49716	A	Corixa Corp	July 12, 2001		
B9	WO	00/61612	A	Corixa Cor.	October 19, 2000		
B10	WO	97/24447	A	Viagene Inc	July 10, 1997		
B11	WO	95/05464	A	Arch Dev Corp	February 23, 1995		
B12	WO	95/03408	A	Dana Farber Cancer Inst Inc	February 2, 1995		

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

COPY

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	1	of	2	Attorney Docket Number	MPI00-212CP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	C1	Database EMBL Sequence Database [Online] Hinxton, UK; 1 June 1999 (1999-06-01) S. Y. Tseng et al.: "Mus Musculus Butyrophilin-like (Btdc) mRNA, Complete cds." EMBL Sequence Accession No. AF142780			
	C2	Database EMBL Sequence Database [Online] Hinxton, UK; 22 February 2000 (2000-02-22) T. Isogai and T. Otsuki: "Homo Sapiens cDNA FLJ11010 fis, clone PLACE1003145; XP002193892. EMBL Sequence Accession No. AK001872			
	C3	Gerstmayer, et al., <i>Cancer Immunology Immunotherapy</i> 45(3-4): 156-158 (1997)			
	C4	Schwartz, et al., <i>Nat. Immunol.</i> 3(5):427-434 (2002)			
	C5	Inobe et al., <i>J. Immunol.</i> 157:582-588 (1996)			
	C6	ABBAS et al., <i>Nature Medicine</i> 5 (12) :1345-1346 (1999)			
	C7	DONG et al., <i>Nature Medicine</i> 5(12) :1365-1369 (1999)			
	C8	FARGEAS et al., <i>J. Exp. Med.</i> 182 :667-675 (1995)			
	C9	FREEMAN et al., <i>The FASEB Journal</i> 14(6) :Abstract 153.34, Pg. A1170 (2000)			
	C10	HUTLOFF et al., <i>Nature</i> 397:263-266 (1999)			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burdén Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(use as many sheets as necessary)					
Sheet	2	of	2	Attorney Docket Number	MPI00-212CP1CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	
	C11	LING et al., <i>J. Immunol.</i> 164(4):1653-1657 (2000)	T ²
	C12	MAGES et al., <i>Eur. J. Immunol.</i> 30 (4) :1040-1047 (2000)	
	C13	PEACH et al., <i>Journal of Biological Chemistry</i> 270(36) :21181-21187 (1995)	
	C14	YOSHINAGA et al., <i>Nature</i> 402(6763) 827-832 (1999)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.